Luspatercept-aamt
REBLOZYL® (
REBLOZYL® (
Dr. Barry Skikne is certified by the American Board of Internal Medicine with a subcertification in hematology. He completed a fellowship at the University of Kansas Medical Center. He earned his medical degree from the University of Witwatersrand and completed his residency at Johannesburg Hospital.
Dr. Malcovati is an Associate Professor of Hematology at the University of Pavia Medical School and with special interest and expertise in myeloid neoplasms, in particular,
Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to
The development in the therapeutic landscape of
Mutations in TP53 are observed in ∼20% of patients with
Dr. Buckstein's research is clinical and focused on novel biological therapies for MDS and lymphomas. She is a clinician-investigator and interacts closely with the scientists of Sunnybrook Research Institute and elsewhere on collaborative projects